Posted on July 13, 2016 by Sitemaster
Back in September 2014, Exelixis had announced (and we had reported) the failure of the COMET-1 trial to show a meaningful survival benefit for treatment with cabozantinib in men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Drugs in development | Tagged: cabozantinib, castration-resistant, metastatic, outcome, publication | 2 Comments »
Posted on December 1, 2014 by Sitemaster
According to a media release from Exelixis in the past hour, it appears that we have seen the end of all attempts to develop cabozantinib as a treatment for metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management | Tagged: cabozantinib, castration-resistant, mCRPC, metastatic | 3 Comments »
Posted on September 2, 2014 by Sitemaster
Exelixis has announced that the COMET-1 trial of cabozantinib in the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC) has failed to show a statistically significant survival benefit. The company has also stopped enrollment into the COMET-2 trial. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: cabozantinib, castration-resistant, mCRPC, metastatic | Leave a comment »
Posted on March 27, 2014 by Sitemaster
Some in the investment community (and probably many in Exelixis itself) had been hoping that an interim analysis of an ongoing Phase III trial of cabozantinib (Cometriq) in the treatment of late-stage prostate cancer would show a positive outcome and allow the trial to be stopped early. … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: cabozantinib, castration-resistant, mCRPC, metastatic | Leave a comment »
Posted on December 2, 2013 by Sitemaster
According to a media release issued earlier today by Exelixis, the company has initiated a randomized Phase II clinical trial of cabozantinib + abiraterone + prednisone (CAP) versus abiraterone + prednisone (AP) in chemotherapy-naive men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, cabozantinib, castration-resistant, chemotherapy-naïve, mCRPC, metastatic | Leave a comment »
Posted on October 18, 2013 by Sitemaster
Regular readers of this blog will be aware that a drug known generically as cabozantinib is in clinical trials for treatment of men with late-stage forms of metastatic, castration-resistant prostate cancer (mCRPC). However, … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: cabozantinib, gene, ras, ret | Leave a comment »
Posted on November 30, 2012 by Sitemaster
The U.S. Food & Drug Administration (FDA) has approved cabozantinib (brand name Cometriq™) for treatment of progressive, metastatic medullary thyroid cancer in the USA. … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: approval, cabozantinib, Cometriq, Exelixis | Leave a comment »
Posted on June 11, 2012 by Sitemaster
According to a recent media release issued by Exelixis, cabozantinib (also known as XL-184) has shown effectiveness in a randomized, Phase III clinical trial in patients with advanced and metastatic medullary thyroid cancer. Obviously this is not metastatic prostate cancer, but these data look good enough for Exelixis to consider a submission for marketing approval. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management | Tagged: cabozantinib, Exelixis, XL-184 | Leave a comment »
Posted on May 30, 2012 by Sitemaster
According to media releases from the relevant companies, two significant trials (of enzalutamide and of cabozantinib) are already or will soon be recruiting men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: cabozantinib, castration-resistant, enzalutamide, MDV3100, metastatic, XL184 | Leave a comment »
Posted on November 14, 2011 by Sitemaster
Additional data about the effectiveness and safety of cabozantinib were reported over the past weekend at a meeting in San Francisco. … READ MORE …
Filed under: Drugs in development, Management, Treatment, Uncategorized | Tagged: cabozantinib, castration-resistant, mCRPC, metastatic, XL184 | 2 Comments »
Posted on November 1, 2011 by Sitemaster
Accoring to a Bloomberg Businessweek report and information on the Exelixis corporate web site, the company is planning two multi-center, randomized, Phase III clinical trials of the investigational agent cabozantinib (a.k.a., XL184) in metastatic, castration-resistant prostate cancer (mCRPC): … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: cabozantinib, mCRPC, pain, Phase III, trial | Leave a comment »
Posted on September 7, 2011 by Sitemaster
Exelexis has issued a media release stating that “the pre-specified number of progression-free survival (PFS) events required for un-blinding of the data for the ongoing Phase III pivotal trial of cabozantinib in patients with medullary thyroid cancer (MTC), known as the EXAM trial, has been reached.” … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: cabozantinib, castration-resistant, metastatic | 5 Comments »
Posted on August 25, 2011 by Sitemaster
A new article on the CancerNetwork.com web site has provided a detailed update on the development of cabozantinib (also known as XL184) for the treatment of late stage prostate cancer. … READ MORE …
Filed under: Drugs in development | Tagged: cabozantinib, XL184 | 2 Comments »
Posted on June 6, 2011 by Sitemaster
A new update was provided at the ASCO meeting today on progress from the Phase II clinical trial of XL184 (cabozantinib) in the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Drugs in development | Tagged: cabozantinib, outcome, XL184 | 2 Comments »
THE "NEW" PROSTATE CANCER INFOLINK 